Immune landscape in invasive ductal and lobular breast cancer reveals a divergent macrophage-driven microenvironment

Sayali Onkar,Jian Cui,Jian Zou,Carly Cardello,Anthony R. Cillo,Mostofa Rafid Uddin,April Sagan,Marion Joy,Hatice U. Osmanbeyoglu,Katherine L. Pogue-Geile,Priscilla F. McAuliffe,Peter C. Lucas,George C. Tseng,Adrian V. Lee,Tullia C. Bruno,Steffi Oesterreich,Dario A. A. Vignali
DOI: https://doi.org/10.1038/s43018-023-00527-w
IF: 22.7
2023-03-17
Nature Cancer
Abstract:T cell-centric immunotherapies have shown modest clinical benefit thus far for estrogen receptor-positive (ER + ) breast cancer. Despite accounting for 70% of all breast cancers, relatively little is known about the immunobiology of ER + breast cancer in women with invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC). To investigate this, we performed phenotypic, transcriptional and functional analyses for a cohort of treatment-naive IDC ( n = 94) and ILC ( n = 87) tumors. We show that macrophages, and not T cells, are the predominant immune cells infiltrating the tumor bed and the most transcriptionally diverse cell subset between IDC and ILC. Analysis of cellular neighborhoods revealed an interplay between macrophages and T cells associated with longer disease-free survival in IDC but not ILC. Our datasets provide a rich resource for further interrogation into immune cell dynamics in ER + IDC and ILC and highlight macrophages as a potential target for ER + breast cancer.
What problem does this paper attempt to address?